Stockscreener 앱 받기
3.89
3.18%
0.12
시간 외 거래:
3.89
전일 마감가:
$3.77
열려 있는:
$3.83
하루 거래량:
1.46M
Relative Volume:
0.62
시가총액:
$259.20M
수익:
$80.00M
순이익/손실:
$-76.12M
주가수익비율:
-3.3929
EPS:
-1.1465
순현금흐름:
$-63.88M
1주 성능:
+8.66%
1개월 성능:
+3.18%
6개월 성능:
-60.06%
1년 성능:
-42.88%
1일 변동 폭
$3.77
$3.91
1주일 범위
$3.544
$3.91
52주 변동 폭
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.89 | 248.54M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ETFs Investing in Fulcrum Therapeutics, Inc. Stocks - TradingView
Fulcrum Therapeutics Inc (FULC) Cash Flow - TradingKey
FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:+0.005 - TradingKey
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation - TMX Newsfile
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: F - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law ViolationsInvestors are Encouraged to Contact the Firm - FinancialContent
TANG CAPITAL MANAGEMENT LLC Increases Stake in Fulcrum Therapeutics Inc. - GuruFocus
Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics - The National Law Review
Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares - Bitget
Fulcrum Therapeutics: director Kevin Tang buys $594k in shares By Investing.com - Investing.com Australia
Form 4 Fulcrum Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics: director Kevin Tang buys $594k in shares - Investing.com
Fulcrum Therapeutics, Inc. (FULC) insider funds purchase 167,616 shares at ~$3.5 - Stock Titan
If You Invested $1,000 in Fulcrum Therapeutics (FULC) - Stock Titan
Fulcrum Therapeutics stock plunges 51% after ha... - Pluang
Kaplan Fox Initiates Probe Into Fulcrum Therapeutics Over Securities Issues After Pociredir Program Halt - Kalkine Media
Fulcrum Therapeutics (FULC) Q1 2026 Earnings: Narrower-Than-Anticipated Loss as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - dars.gov.et
Kaplan Fox Initiates Securities Probe into Fulcrum Therapeutics After 51% Stock Plunge Post-Pociredir Program Halt - Kalkine Media
BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC) - Stock Titan
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation - NewMediaWire
Kevin Tang buys $891k of Fulcrum Therapeutics stock By Investing.com - Investing.com Canada
Kevin Tang buys $891k of Fulcrum Therapeutics stock - Investing.com
Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder - Stock Titan
Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys - Stock Titan
Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake - Stock Titan
Frontier tech research, news & data - MLQ.ai
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fulcrum Therapeutics (FULC) Slides 3.7% as Sellers Test Key Support Near $3.45Charm Flow - dars.gov.et
Fulcrum Therapeutics Inc. (FULC) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionRevenue Surprise History - dars.gov.et
Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan
Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan
Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K. - Moomoo
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
Fulcrum Therapeutics | 8-K: Current report - Moomoo
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fulcrum Therapeutics Inc 주식 (FULC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | 10% Owner |
Jul 17 '26 |
Buy |
3.52 |
50,945 |
179,326 |
7,080,945 |
| TANG KEVIN | 10% Owner |
Jul 14 '26 |
Buy |
3.57 |
129,603 |
462,906 |
6,805,952 |
| TANG KEVIN | 10% Owner |
Jul 15 '26 |
Buy |
3.56 |
107,377 |
382,262 |
6,913,329 |
| TANG KEVIN | 10% Owner |
Jul 13 '26 |
Buy |
3.54 |
12,966 |
45,900 |
6,676,349 |
| Ezekowitz Alan | Director |
Jun 26 '26 |
Sale |
3.65 |
18,000 |
65,614 |
10,927 |
1.84%
0.86%
자본화:
|
볼륨(24시간):